The Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins is dedicated to cancer research, education and training, and care, with an overarching goal of expeditiously and strategically applying new knowledge to improve prevention, screening, detection, diagnosis and treatment of cancer in Maryland and throughout nation and the world. Through targeted outreach and research, cancer outcomes disparities are decreasing in SKCCC's catchment area, but they remain a challenge and a focus at SKCCC. This application requests continued Cancer Center Support Grant (CCSG) funding for SKCCC's Research Programs and Cores. The SKCCC comprises a multidisciplinary, interdepartmental center of The Johns Hopkins University (JHU), encompassing 34 departments in five schools. The scientific Programs of the SKCCC organize and orient the broad base of cancer research throughout JHU into teams focused on rapid translation to the clinic and to populations inside and outside its catchment area. Research conducted at SKCCC includes discovery research into the molecular genetics of human tumorigenesis, clinical trials of new cancer treatments and epidemiologic analyses of lifestyle influences on cancer mortality. The SKCCC is a leading cancer center that is providing insights into the fundamental nature of different cancers and elucidating the thousands of somatic genetic and epigenetic alterations that mark the differences from case to case. This body of work has fueled an emerging understanding that the ultimate control of cancer will require individualizing cancer care using approaches that can be deployed at a population scale. To accomplish this mission, SKCCC took critical input from its External Advisory Board and has strategically evolved since the last CCSG to: 1) augment the clinical and population impact of the discovery pipeline in cancer genetics, epigenetics and immunology generated by discipline-oriented Programs; 2) maximize the translational research output of disease-specific Programs, emphasizing the exploration of new concepts in scientifically driven clinical trials; and 3) position the population-oriented Program to identify, understand and overcome barriers responsible for disparities in cancer outcome in the catchment area. The nine SKCCC Research Programs include four discipline-oriented Programs: Cancer Biology (CB; Baylin, Velculescu), Cancer Immunology (CI; Pardoll, Drake), Cancer Molecular and Functional Imaging (CMFI; Bhujwalla, Pomper), and Cancer Chemical and Structural Biology (CCSB; Berger, Liu); four disease- specific Programs: Hematologic Malignancies and Bone Marrow Transplantation (HMBMT; Ambinder, Jones, Levis), Prostate Cancer (PC; Pienta, Denmeade, Lupold), Breast and Ovarian Cancer (BOC; Stearns, Shih), and Brain Cancer (BC; Grossman, Brem, Laterra); and one population-oriented Program: Cancer Prevention and Control (CPC; Platz, Roden). These Programs are supported by fifteen Cores, one developing Core (described in Developmental Funds) and a dedicated leadership team.
(Public Health Relevance Statement) Cancer is a leading cause of death in the U.S. and throughout the world. With the tremendous medical advances over the past 50 years, the U.S. population's life expectancy has dramatically increased, but because the incidence of most cancers increases with age, cancers have become a profound challenge to the U.S. health care system. Minorities suffer a disproportionate burden of the cancer threat with disparate outcomes for many cancer types. To meet these challenges, dedicated cancer research at the SKCCC and elsewhere over the past 35 years has generated fundamental insights into the molecular mechanisms that cause human cancers to arise, progress and threaten life. These discoveries create new opportunities to improve screening, detection, diagnosis, prevention and treatment.
| Rowe, Steven P; Luber, Brandon; Makell, Monique et al. (2018) From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol 12:1661-1672 |
| Martin, Allison M; Nirschl, Christopher J; Polanczyk, Magda J et al. (2018) PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget 9:19177-19191 |
| Yeruva, Sri Lakshmi Hyndavi; Javadi, Mehrbod Som; Stearns, Vered (2018) Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report. Clin Breast Cancer 18:e277-e280 |
| Zarif, Jelani C; Chalfin, Heather J; Pierorazio, Phillip M et al. (2018) Characterization of the Macrophage Infiltrate in a Case of Xanthogranulomatous Pyelonephritis. J Clin Urol 11:226-228 |
| Shah, Tariq; Krishnamachary, Balaji; Wildes, Flonne et al. (2018) Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells. NMR Biomed 31:e3936 |
| Chung, Liam; Thiele Orberg, Erik; Geis, Abby L et al. (2018) Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe 23:203-214.e5 |
| LaFleur, Martin W; Muroyama, Yuki; Drake, Charles G et al. (2018) Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol 200:375-383 |
| McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629 |
| Popovic, Aleksandra; Jaffee, Elizabeth M; Zaidi, Neeha (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209-3218 |
| Peprah, Sally; Curreiro, Frank C; Hayes, Jennifer H et al. (2018) A spatiotemporal analysis of invasive cervical cancer incidence in the state of Maryland between 2003 and 2012. Cancer Causes Control 29:445-453 |
Showing the most recent 10 out of 2393 publications
